Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Literature Pre-COVID-19.
Identifieur interne : 000A33 ( Main/Curation ); précédent : 000A32; suivant : 000A34Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Literature Pre-COVID-19.
Auteurs : Georgi Fram [États-Unis] ; Dee Dee Wang [États-Unis] ; Kelly Malette [États-Unis] ; Pedro Villablanca [États-Unis] ; Guson Kang [États-Unis] ; Kent So [États-Unis] ; Mir B. Basir [États-Unis] ; Arfaat Khan [États-Unis] ; John E. Mckinnon [États-Unis] ; Marcus Zervos [États-Unis] ; William W. O'Neill [États-Unis]Source :
- Current cardiology reviews [ 1875-6557 ] ; 2020.
Abstract
INTRODUCTION
Hydroxychloroquine has been used for rheumatological diseases for many decades and is considered a safe medication. With the COVID-19 outbreak, there has been an increase in reports associating cardiotoxicity with hydroxychloroquine. It is unclear if cardiotoxic profile of hydroxychloroquine is previously underreported in the literature, or a new manifestation of COVID-19 and therapeutic interventions. This manuscript evaluates the incidence of cardiotoxicity associated with hydroxychloroquine prior to onset of COVID-19.
METHODS
PubMED, EMBASE, and Cochrane databases were searched for keywords derived from MeSH terms, prior to 4/9/2020. Inclusion eligibility was based on appropriate reporting of cardiac conditions and study design.
RESULTS
Sixty-nine articles were identified (58 case reports, 11 case series). Majority (84%) of patients were female, with a median age of 49.2(range 16-92) years. Fifteen of 185 patients with cardiotoxic events were in the setting of acute intentional overdose. In acute overdose, the median ingestion was 17,857 14,873 mg. Two of 15 patients died after acute intoxication. In patients with long-term hydroxychloroquine use (10.5 ± 8.9 years), new onset systolic heart failure occurred in 54 of 155 patients (35%) with median cumulative ingestion of 1,493,800 ± 995,517 mg. The majority of patients improved with withdrawal of hydroxychloroquine and standard therapy.
CONCLUSIONS
Millions of hydroxychloroquine doses are prescribed annually. Prior to COVID-19 pandemic, cardiac complications attributed to hydroxychloroquine were uncommon. Further studies are needed to understand the impact of COVID-19 on the cardiovascular system to understand presence or absence of potential medication interactions with hydroxychloroquine in this new pathophysiological state.
DOI: 10.2174/1573403X16666201014144022
PubMed: 33059567
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A33
Links to Exploration step
pubmed:33059567Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Literature Pre-COVID-19.</title><author><name sortKey="Fram, Georgi" sort="Fram, Georgi" uniqKey="Fram G" first="Georgi" last="Fram">Georgi Fram</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Wang, Dee Dee" sort="Wang, Dee Dee" uniqKey="Wang D" first="Dee Dee" last="Wang">Dee Dee Wang</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Malette, Kelly" sort="Malette, Kelly" uniqKey="Malette K" first="Kelly" last="Malette">Kelly Malette</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Villablanca, Pedro" sort="Villablanca, Pedro" uniqKey="Villablanca P" first="Pedro" last="Villablanca">Pedro Villablanca</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Kang, Guson" sort="Kang, Guson" uniqKey="Kang G" first="Guson" last="Kang">Guson Kang</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="So, Kent" sort="So, Kent" uniqKey="So K" first="Kent" last="So">Kent So</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Basir, Mir B" sort="Basir, Mir B" uniqKey="Basir M" first="Mir B" last="Basir">Mir B. Basir</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Khan, Arfaat" sort="Khan, Arfaat" uniqKey="Khan A" first="Arfaat" last="Khan">Arfaat Khan</name><affiliation wicri:level="2"><nlm:affiliation>Section of Cardiac Electrophysiology, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Section of Cardiac Electrophysiology, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Mckinnon, John E" sort="Mckinnon, John E" uniqKey="Mckinnon J" first="John E" last="Mckinnon">John E. Mckinnon</name><affiliation wicri:level="2"><nlm:affiliation>Divison of Infectious Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Divison of Infectious Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Zervos, Marcus" sort="Zervos, Marcus" uniqKey="Zervos M" first="Marcus" last="Zervos">Marcus Zervos</name><affiliation wicri:level="2"><nlm:affiliation>Divison of Infectious Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Divison of Infectious Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="O Neill, William W" sort="O Neill, William W" uniqKey="O Neill W" first="William W" last="O'Neill">William W. O'Neill</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33059567</idno><idno type="pmid">33059567</idno><idno type="doi">10.2174/1573403X16666201014144022</idno><idno type="wicri:Area/Main/Corpus">000A33</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A33</idno><idno type="wicri:Area/Main/Curation">000A33</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000A33</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Literature Pre-COVID-19.</title><author><name sortKey="Fram, Georgi" sort="Fram, Georgi" uniqKey="Fram G" first="Georgi" last="Fram">Georgi Fram</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Wang, Dee Dee" sort="Wang, Dee Dee" uniqKey="Wang D" first="Dee Dee" last="Wang">Dee Dee Wang</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Malette, Kelly" sort="Malette, Kelly" uniqKey="Malette K" first="Kelly" last="Malette">Kelly Malette</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Villablanca, Pedro" sort="Villablanca, Pedro" uniqKey="Villablanca P" first="Pedro" last="Villablanca">Pedro Villablanca</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Kang, Guson" sort="Kang, Guson" uniqKey="Kang G" first="Guson" last="Kang">Guson Kang</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="So, Kent" sort="So, Kent" uniqKey="So K" first="Kent" last="So">Kent So</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Basir, Mir B" sort="Basir, Mir B" uniqKey="Basir M" first="Mir B" last="Basir">Mir B. Basir</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Khan, Arfaat" sort="Khan, Arfaat" uniqKey="Khan A" first="Arfaat" last="Khan">Arfaat Khan</name><affiliation wicri:level="2"><nlm:affiliation>Section of Cardiac Electrophysiology, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Section of Cardiac Electrophysiology, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Mckinnon, John E" sort="Mckinnon, John E" uniqKey="Mckinnon J" first="John E" last="Mckinnon">John E. Mckinnon</name><affiliation wicri:level="2"><nlm:affiliation>Divison of Infectious Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Divison of Infectious Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Zervos, Marcus" sort="Zervos, Marcus" uniqKey="Zervos M" first="Marcus" last="Zervos">Marcus Zervos</name><affiliation wicri:level="2"><nlm:affiliation>Divison of Infectious Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Divison of Infectious Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="O Neill, William W" sort="O Neill, William W" uniqKey="O Neill W" first="William W" last="O'Neill">William W. O'Neill</name><affiliation wicri:level="2"><nlm:affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Center for Structural Heart Disease, Henry Ford Health System, Detroit</wicri:cityArea></affiliation></author></analytic><series><title level="j">Current cardiology reviews</title><idno type="eISSN">1875-6557</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>Hydroxychloroquine has been used for rheumatological diseases for many decades and is considered a safe medication. With the COVID-19 outbreak, there has been an increase in reports associating cardiotoxicity with hydroxychloroquine. It is unclear if cardiotoxic profile of hydroxychloroquine is previously underreported in the literature, or a new manifestation of COVID-19 and therapeutic interventions. This manuscript evaluates the incidence of cardiotoxicity associated with hydroxychloroquine prior to onset of COVID-19.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>PubMED, EMBASE, and Cochrane databases were searched for keywords derived from MeSH terms, prior to 4/9/2020. Inclusion eligibility was based on appropriate reporting of cardiac conditions and study design.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Sixty-nine articles were identified (58 case reports, 11 case series). Majority (84%) of patients were female, with a median age of 49.2(range 16-92) years. Fifteen of 185 patients with cardiotoxic events were in the setting of acute intentional overdose. In acute overdose, the median ingestion was 17,857 14,873 mg. Two of 15 patients died after acute intoxication. In patients with long-term hydroxychloroquine use (10.5 ± 8.9 years), new onset systolic heart failure occurred in 54 of 155 patients (35%) with median cumulative ingestion of 1,493,800 ± 995,517 mg. The majority of patients improved with withdrawal of hydroxychloroquine and standard therapy.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Millions of hydroxychloroquine doses are prescribed annually. Prior to COVID-19 pandemic, cardiac complications attributed to hydroxychloroquine were uncommon. Further studies are needed to understand the impact of COVID-19 on the cardiovascular system to understand presence or absence of potential medication interactions with hydroxychloroquine in this new pathophysiological state.</p></div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">33059567</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-6557</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Current cardiology reviews</Title><ISOAbbreviation>Curr Cardiol Rev</ISOAbbreviation></Journal><ArticleTitle>Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Literature Pre-COVID-19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/1573403X16666201014144022</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Hydroxychloroquine has been used for rheumatological diseases for many decades and is considered a safe medication. With the COVID-19 outbreak, there has been an increase in reports associating cardiotoxicity with hydroxychloroquine. It is unclear if cardiotoxic profile of hydroxychloroquine is previously underreported in the literature, or a new manifestation of COVID-19 and therapeutic interventions. This manuscript evaluates the incidence of cardiotoxicity associated with hydroxychloroquine prior to onset of COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMED, EMBASE, and Cochrane databases were searched for keywords derived from MeSH terms, prior to 4/9/2020. Inclusion eligibility was based on appropriate reporting of cardiac conditions and study design.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-nine articles were identified (58 case reports, 11 case series). Majority (84%) of patients were female, with a median age of 49.2(range 16-92) years. Fifteen of 185 patients with cardiotoxic events were in the setting of acute intentional overdose. In acute overdose, the median ingestion was 17,857 14,873 mg. Two of 15 patients died after acute intoxication. In patients with long-term hydroxychloroquine use (10.5 ± 8.9 years), new onset systolic heart failure occurred in 54 of 155 patients (35%) with median cumulative ingestion of 1,493,800 ± 995,517 mg. The majority of patients improved with withdrawal of hydroxychloroquine and standard therapy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Millions of hydroxychloroquine doses are prescribed annually. Prior to COVID-19 pandemic, cardiac complications attributed to hydroxychloroquine were uncommon. Further studies are needed to understand the impact of COVID-19 on the cardiovascular system to understand presence or absence of potential medication interactions with hydroxychloroquine in this new pathophysiological state.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fram</LastName><ForeName>Georgi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dee Dee</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malette</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villablanca</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Guson</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>So</LastName><ForeName>Kent</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basir</LastName><ForeName>Mir B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Arfaat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Cardiac Electrophysiology, Henry Ford Health System, Detroit, Michigan. United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKinnon</LastName><ForeName>John E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Divison of Infectious Disease, Henry Ford Health System, Detroit, Michigan. United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zervos</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Divison of Infectious Disease, Henry Ford Health System, Detroit, Michigan. United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neill</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan. United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Cardiol Rev</MedlineTA><NlmUniqueID>101261935</NlmUniqueID><ISSNLinking>1573-403X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical cardiology</Keyword><Keyword MajorTopicYN="N">SLE.</Keyword><Keyword MajorTopicYN="N">cardiac complications</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">infectious disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>08</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>16</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33059567</ArticleId><ArticleId IdType="pii">CCR-EPUB-110663</ArticleId><ArticleId IdType="doi">10.2174/1573403X16666201014144022</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000A33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:33059567
|texte= Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Literature Pre-COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:33059567" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |